Consumer Marketing briefs

Share this article:
UCB, Sanofi-Aventis refreshed their My Xperts program, an online resource backing Xyzal (levocetirizine dihydrochloride), for the fall allergy season. The back-to-school-themed content offers tips to parents from a team of indoor and outdoor nasal allergy experts, noting that an estimated 10,000 children miss school each day in the US due to nasal allergies.

PhRMA said a proposed FDA study of benefit information in DTC print and TV ads doesn't appear to meet the Paperwork Reduction Act standard of being necessary for the proper performance of agency functions and having practical utility. By limiting itself to how consumers distinguish between low- versus high-efficacy products in ads, PhRMA said the study overlooks the fact that such ads are a device to move consumers to begin a conversation with healthcare professionals.

AstraZeneca is touring a bipolar education and awareness exhibit dubbed The Bipolar Journey: Living with Bipolar Depression. The interactive exhibit employes imagery, multimedia activities and interactive tools to “help patients connect with experts as well other patients and caregivers” who have dealt with bipolar depression.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?